Have We Forgotten the Purpose of Phase III Studies?
- 10 December 2007
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (35) , 5553-5555
- https://doi.org/10.1200/jco.2007.13.7810
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Have We Forgotten the Purpose of Phase III Studies?Journal of Clinical Oncology, 2007
- Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemiaOncogene, 2007
- Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997Journal of Clinical Oncology, 2007
- Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H)Clinical Cancer Research, 2006
- Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted TherapyJournal of Clinical Oncology, 2006
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood, 2002
- Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000
- Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.Journal of Clinical Oncology, 1997
- Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.Journal of Clinical Oncology, 1997
- Primary Structure of CD52Journal of Biological Chemistry, 1995